Abstract
This study was conducted to compare the efficacy of intravenous diphenhydramine with dihydroergotamine mesylate (DHE-45; Novartis International AG, Switzerland) in the treatment of severe, refractory, migraine headache. A retrospective review was conducted to include eighty randomly chosen patients who were admitted to the Michigan Head Pain & Neurological Institute's inpatient program at Chelsea Community Hospital. Patients had received nine doses of diphenhydramine or nine doses of DHE-45 during a 3-day period. Patients receiving DHE-45 also received metoclopramide (Reglan; AH Robins Company, Inc., Richmond, VA) as prophylaxis for nausea. Demographics, headache diagnosis, psychiatric discharge diagnoses, abortive medications, and adverse events were recorded and assessed.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Analgesics, Non-Narcotic / administration & dosage*
-
Analgesics, Non-Narcotic / adverse effects
-
Analgesics, Non-Narcotic / therapeutic use
-
Antiemetics / therapeutic use
-
Dihydroergotamine / administration & dosage*
-
Dihydroergotamine / adverse effects
-
Dihydroergotamine / therapeutic use
-
Diphenhydramine / administration & dosage*
-
Diphenhydramine / adverse effects
-
Diphenhydramine / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Histamine H1 Antagonists / administration & dosage*
-
Histamine H1 Antagonists / adverse effects
-
Histamine H1 Antagonists / therapeutic use
-
Humans
-
Injections, Intravenous
-
Male
-
Metoclopramide / therapeutic use
-
Middle Aged
-
Migraine Disorders / drug therapy*
-
Migraine Disorders / physiopathology*
-
Nausea / prevention & control
Substances
-
Analgesics, Non-Narcotic
-
Antiemetics
-
Histamine H1 Antagonists
-
Dihydroergotamine
-
Diphenhydramine
-
Metoclopramide